Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein
Authors:
- 1 September 2010
- journal article
- Published by Springer Nature in Cytotechnology
- Vol. 62 (5) , 431-438
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor‐mediated cAMP pathwayMolecular Carcinogenesis, 2007
- A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancerInvestigational New Drugs, 2006
- Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expressionAnnals of Oncology, 2006
- Radiosensitivity Enhancement by Combined Treatment of Celecoxib and Gefitinib on Human Lung Cancer CellsClinical Cancer Research, 2006
- Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex® in the treatment of human nasopharyngeal carcinomaInternational Journal of Molecular Medicine, 2005
- In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma CellsClinical Cancer Research, 2005
- RETRACTED: Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with lymph node metastasisOral Oncology, 2005
- Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: Clinical and in vitro studiesHead & Neck, 2005
- Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- Many actions of cyclooxygenase‐2 in cellular dynamics and in cancerJournal of Cellular Physiology, 2002